Menu

 

Research News

Therapeutic manipulation of HDL fails to benefit adults with heart disease

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e7643 (Published 13 November 2012)
Cite this as: BMJ 2012;345:e7643

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

N Engl J Med2012; doi:10.1056/NEJMoa1206797

Dalcetrapib increases serum concentrations of high density lipoprotein (HDL) cholesterol, and Hoffmann-La Roche developed this new drug in response to observational evidence that higher concentrations were associated with a lower risk of cardiovascular disease. Dalcetrapib failed to prevent cardiovascular …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Subscribe

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

Latest comments and most commented

THIS WEEK'S POLL

Read related article

See previous polls